Lab21 acquires NPTech Ltd and appoints corporate advisors for European M&A activity
Lab21 has acquired NPTech Ltd, an independent clinical laboratory company providing diagnostic testing services for the NHS and private healthcare providers in the UK and parts of Europe. The acquisition of NPTech, in an undisclosed financial transaction, significantly broadens Lab21's range of diagnostic tests, according to the company. NPTech brings food intolerance testing; chemical and mould sensitivity testing; blood tests for a range of conditions; basic clinical chemistry; and salivary hormone testing.
Lab21 now has the ability to test for intolerances to over 100 food products and 50 chemicals including food colourings (E-numbers), antibiotics, anti-inflammatories and environmental chemicals. In addition, NPTech has multiple other diagnostic tests for a variety of clinical disorders including salivary tests for adrenal hormones, sex hormones and sleep disturbance together with a range of clinical biochemistry blood testing, particularly in the area of thyroid disease diagnosis and management. In addition to the range of tests, Lab21 will also benefit from the skills and experience of senior staff at NPTech, including Ron Turner who founded the company in 2002 and who will become Laboratory Director at Lab21.
Lab21 has also appointed, BDO Stoy Hayward LLP to lead its M&A activity in Europe. Peter Hemington, Corporate Finance Partner at BDO commented: "We are delighted to be chosen by Lab21 in pursuit of its aggressive M&A strategy for 2008 and excited to be working in the sectors of healthcare diagnostics and environmental monitoring."
Other news from the department business & finance
Most read news
More news from our other portals
See the theme worlds for related content
Last viewed contents
Analytik Jena Sells Site in Eisfeld - New investor acquiring entire Optics business unit as well as component production for analytical technology
Toxic agents behind Parkinson's disease seen at work for the first time - First look at how toxic protein clusters disrupt the membranes of healthy brain cells.
Ocean Optics Employee Wins Global Technology Award - Nelson Chandler takes £20K top prize from multi-national technology company
Measuring the magnetism of antimatter - Researchers measure antiprotons more accurately than ever before
KRÜSS is one of the innovation leaders in 2018 - TOP 100 competition success
COVID-19 : Measuring viral RNA to predict which patients will die - A statistical model uses a blood biomarker of SARS-CoV-2 to identify infected patients who are most at risk of dying of COVID-19
Sperm navigation in 3D
Epigenomics AG Receives Allowance for Key Technology Patent in Japan - Patent broadly covers HeavyMethyl, a core technology of Epigenomics' molecular diagnostic products
